KEYNOTE-522: Pembrolizumab in Triple-Negative Breast Cancer

Opinion
Video

Erika P. Hamilton, MD, and the Oncology Brothers offer clinical insights on recent data from KEYNOTE-522 on pembrolizumab in patients with triple-negative breast cancer.

Newsletter

Stay up to date on practice-changing data in community practice.

Recent Videos
Related Content